Brief: Alzamend Neuro Announces Dosing Of First Patient In Phase II Clinical Trial Of Al001 “Lithium In Brain” Study
29/05/2025 13:27
May 29 (Reuters) - Alzamend Neuro Inc ALZN.O: ALZAMEND NEURO ANNOUNCES DOSING OF FIRST PATIENT IN ITS PHASE II CLINICAL TRIAL OF AL001 “LITHIUM IN BRAIN” STUDY TAKING PLACE AT MASSACHUSETTS GENERAL HOSPITAL ALZAMEND NEURO INC - TOPLINE DATA EXPECTED BY YEAR END Source text: ID:nGNX2BFhNL Further company coverage: ALZN.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Alzamend Neuro
See all newsAlzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 23 cents a share - Earnings Preview
Alzamend Neuro Inc expected to post a loss of 56 cents a share - Earnings Preview
Alzamend Neuro Inc reports results for the quarter ended April 30 - Earnings Summary
Alzamend Neuro Inc expected to post a loss of 67 cents a share - Earnings Preview